NCT05805358View on ClinicalTrials.gov

Hyperpolarized 13C MRI for Cancer Immunotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Gynecologic CancerCervical CancerEndometrial CancerOvarian Cancer
Interventions
DRUG

Hyperpolarized 13C-Pyruvate injection

DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan

All Listed Sponsors
collaborator

National Science and Technology Council

FED

lead

Chang Gung Memorial Hospital

OTHER

NCT05805358 - Hyperpolarized 13C MRI for Cancer Immunotherapy | Biotech Hunter | Biotech Hunter